Impact of timing of atrial fibrillation, CHA2DS2-VASc score and cancer therapeutics on mortality in oncology patients

ObjectivesTo investigate timing and age distribution of atrial fibrillation (AF) in selected oncology patients, and the impact of AF timing, CHA2DS2-VASc score and cancer therapeutics on mortality.MethodsThis is a retrospective cohort study of oncology patients referred to the cardio-oncology servic...

Full description

Saved in:
Bibliographic Details
Published in:Open heart 2020-11, Vol.7 (2)
Main Authors: Hussain, Muzna, Misbah, Rabel, Donnellan, Eoin, Alkharabsheh, Saqer, Hou, Yuan, Cheng, Feixiong, Crookshanks, Michael, Watson, Chris J, Toth, Andrew J, Houghtaling, Penny, Moudgil, Rohit, Budd, G Thomas, Tang, W H Wilson, Kwon, Deborah H, Jaber, Wael, Griffin, Brian, Kanj, Mohamad, Collier, Patrick
Format: Article
Language:English
Subjects:
Age
Arrhythmias and Sudden Death
Body mass index
Cancer therapies
Cardiac arrhythmia
Cardiovascular disease
Chemotherapy
Electrocardiography
Leukemia
Medical diagnosis
Mortality
Oncology
Patients
Population
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesTo investigate timing and age distribution of atrial fibrillation (AF) in selected oncology patients, and the impact of AF timing, CHA2DS2-VASc score and cancer therapeutics on mortality.MethodsThis is a retrospective cohort study of oncology patients referred to the cardio-oncology service from 2011 to 2018 for echocardiographic cardiosurveillance and/or pre-existing cardiovascular risk factor/disease management. Rates of first AF diagnosis was assessed using a parametric multiphase hazard model (predictive modelling) and non-parametrically by Kaplan-Meier with transformations tested using a bootstrap methodology.ResultsAmong 6754 patients identified, 174 patients had their first AF diagnosis before cancer while 609 patients had their first diagnosis of AF after cancer. Most first AF diagnosis occurred at/early after cancer diagnosis. Increasing AF prevalence at time of cancer diagnosis was seen across older age groups ranges. Diagnosis of cancer at an older age and exposure to cardiotoxic treatment (anthracyclines, HER2-neu inhibitors, tyrosine kinase inhibitors including ibrutinib and radiation) were associated with an increased risk of AF.Modelling of the hazard function of AF identified a high left-skewed peak within 3 years after cancer diagnosis (‘early phase’), followed by a gradual late slight rise 3 years after cancer diagnosis (‘late phase’). AF diagnosis was only associated with death in the early phase (p
ISSN:2398-595X
2053-3624
DOI:10.1136/openhrt-2020-001412